Biography

Dr. Amyn Habib is an Associate Professor in the Department of Neurology at UT Southwestern Medical Center, and a Staff Physician at the VA North Texas Health Care System/ Dallas VA Medical Center. As a physician scientist, Dr. Habib attends to patients with neurological disorders and also runs an active basic science research laboratory.

He received his medical degree from Dow Medical College in Karachi, Pakistan. He did his internship at Henry Ford Hospital in Detroit, followed by a Neurology Residency at the University of Chicago Medical Center.  He then undertook research fellowships at the University of Chicago and at Beth Israel Deaconess Medical Center/Harvard Medical School.  He was an Instructor of Neurology at Harvard Medical School prior to joining UT Southwestern.

His research interests include investigation of growth factor signaling pathways in glioblastoma and other cancers. His work has elucidated the interaction between normal and mutant epidermal growth factor receptors (EGFR) in glioblastoma.  In addition, his laboratory has identified and characterized interactions between inflammatory and oncogenic signaling pathways in cancer.  His laboratory has provided a fundamental insight in the biology of EGFR signaling by demonstrating that constitutive and ligand-induced EGFR signaling triggers distinct and mutually exclusive downstream signaling networks.   More recent work in his laboratory has focused on mechanisms of resistance to targeted treatment in cancer with a particular focus on glioblastoma and lung cancer and identified therapeutic approaches to overcome the resistance of glioblastoma and non-small cell lung cancer (NSCLC) to EGFR inhibition.   Additional areas of active interest in the laboratory include mechanisms that regulate the invasion and proliferation of tumor cells in glioblastoma.  His research is funded by the NIH and by the Department of Veteran’s Affairs.

Education

Medical School
Dow Medical College - Pakistan (1986), Medicine

Research Interest

  • Mechanisms of resistance to targeted treatment in cancer
  • Molecular Mechanisms regulating glioblastoma invasion and proliferation
  • The role of inflammation in gliomagenesis

Publications

Featured Publications LegendFeatured Publications

Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion.
Liu Y, Wang L, Song Q, Ali M, Crowe WN, Kucera GL, Hawkins GA, Soker S, Thomas KW, Miller LD, Lu Y, Bellinger CR, Zhang W, Habib AA, Petty WJ, Zhao D, Nat Nanotechnol 2021 Dec
Elimination of radiation-induced senescence in the brain tumor microenvironment attenuates glioblastoma recurrence.
Fletcher-Sananikone E, Kanji S, Tomimatsu N, Macedo Di Cristofaro LF, Kollipara RK, Saha D, Floyd JR, Sung P, Hromas R, Burns TC, Kittler R, Habib AA, Mukherjee B, Burma S, Cancer Res 2021 Sep
Itraconazole Exerts its Anti-Tumor Effect in Esophageal Cancer by Suppressing the HER2/AKT Signaling Pathway.
Zhang W, Bhagwath AS, Ramzan Z, Williams TA, Subramaniyan I, Edpuganti V, Kallem RR, Dunbar KB, Ding P, Gong K, Geurkink SA, Beg MS, Kim J, Zhang Q, Habib AA, Choi SH, Lapsiwala R, Bhagwath G, Dowell JE, Melton SD, Jie C, Putnam WC, Pham TH, Wang DH, Mol Cancer Ther 2021 Aug
Tumor necrosis factor in lung cancer: Complex roles in biology and resistance to treatment.
Gong K, Guo G, Beckley N, Zhang Y, Yang X, Sharma M, Habib AA, Neoplasia 2020 Dec 23 2 189-196

Honors & Awards

  • Clinical Investigator Award
    National Cancer Institute (1999)